Getting to Know Mary Kunjappu, an Alexion R&D Leading Voice
Science is hard, but rare disease research and development (R&D) stands apart. Because individual patient populations are small and many rare diseases are not well understood, research in this space can often bring added complexity. Mary Kunjappu is a Medical Director in our Medical Affairs team in the US. We spoke with her about the importance of following the science, expecting the unexpected, and the endless possibilities in rare disease research.
How did you get involved in medical affairs?
I'm a bench scientist by training, and towards the end of my PhD, I got very interested in clinical research and the potential for things at the bench to have therapeutic effects. And after graduate school, I started working in medical communications because I was very passionate about talking about the science itself. I started working in rare diseases and I got the opportunity to come in-house with Alexion. I’ve been here for almost seven years now.
What led you to a job in rare disease, specifically?
[When] I started working in rare diseases, I really fell in love with the impact it can make and the work that we do for patients and families because many rare diseases are not well known, we get an opportunity to start educating healthcare providers and really, at the early stages, defining different aspects of the disease and what are the symptoms.
What about your work excites you?
I think it gets back to the impact we can make in rare disease where there is often nothing previously existing to help some of these patients, and we’re able to fill that gap. It’s a very unique position to be in.
What’s one lesson you’ve learned from working in rare disease R&D?
It’s all about following the science, even if it takes you to unexpected places. You need to be able to say, “this is where this is leading us, this is what we're learning about this, and the best way for us to understand this molecule,” and be open to making a change.
I’ve learned to really focus on what the information is, and what it is telling us, rather than having preconceived notions of where things should be, and really tailoring and figuring out what the next step should be.
Do you have any advice for someone considering a career in rare disease R&D?
There’re so many new things happening in science that if it doesn't exist today, it may exist tomorrow. Whatever different combination of interests you are thinking about is probably going to happen in the future. Don't limit yourself to what is possible today.
Learn more about our scientists, innovative culture, career opportunities at Alexion.
More articles you may like
Article • June 08, 2026
From Unseen to Seen: Why Making Rare Diseases Visible Matters for Access to Care in the United States
Across the United States, more than 30 million people are living with a rare disease.1 Yet for too many patients and their families, these conditions remain unrecognized within healthcare systems. On average, an accurate diagnosis can take five years or more, though access to care varies by geography, and the full physical, social and economic impact of rare diseases is obscured by fragmented data systems.
Article • May 18, 2026
Caring for the Caregivers: Mental Health in Rare Disease
Across the United States, millions of families are navigating the complexities of rare disease. Behind many of these journeys is a caregiver coordinating appointments, advocating for access and care, balancing responsibilities at home and work, and carrying a significant emotional load.
Recognizing the toll these challenges can have on families, Alexion, AstraZeneca Rare Disease collaborated with caregivers and mental health professionals to develop More Than Rare, a three-part webinar series focused on patient and caregiver mental health.
Article • May 11, 2026
Tina’s Big Trip: A rare disease story about going the extra mile
Tina’s Big Trip: A rare disease story about going the extra mile, is the newest title in Alexion, AstraZeneca Rare Disease’s Inspired By book series created to support the rare disease community, and especially families impacted by rare diseases. The story, which follows two sisters preparing for a journey to Italy with their father, reflects the daily resilience that families demonstrate while managing the unseen complexities of living with a rare disease.
Article • February 03, 2026
Advancing Policy, Partnerships and Progress for the Rare Disease Community
As we reflect ahead of Rare Disease Day, we reaffirm our commitment to pioneering innovations for the rare disease community and to shortening the time to diagnosis, improving access to lifesaving care, and advancing health care policies that support patients and families.
Clinical Trials • October 28, 2025
Shaping the future of R&D with real world insights into rare disease
Studying a rare disease often involves working with fragmented information, much like piecing together scattered pages of different books, each offering part of the story but rarely forming a complete picture. Researchers face this challenge due to small, often underdiagnosed, patient populations and limited understanding of how these diseases progress over time.
Diagnostics • September 17, 2025
Genomic Innovation to Support Newborn Screening of Rare Diseases
Today, while more than 10,000 rare diseases are known, recommended newborn screening panels cover only about 40 core conditions. This gap underscores the need for innovative approaches to expand the reach of newborn screening.
Thought Leadership • June 11, 2025
Paving Regulatory Pathways in Rare Disease
Many rare disease medicines are often a first of their kind, and a clear roadmap for their development and approval does not exist. Navigating the complex and sometimes unprecedented regulatory environment for rare disease requires innovation, collaboration and a patient-first mindset.
Media [News] • April 10, 2025
Advancing Rare Disease Research Through Patient-Centric Trial Design
As Head of Development, Regulatory and Safety at Alexion, Gianluca Pirozzi channels his life’s experience with rare disease to inform his work at Alexion, ensuring clinical programmes are fueled by a patient-focused mindset.
Article • February 24, 2025
Supporting Patients on Rare Disease Day, and Every Day
Rare Disease Day recognizes the 400 million people worldwide – and 30 million in the United States – who are living with a rare disease. While significant progress has been made in understanding rare diseases and developing treatments, the need for continued awareness, research and support is as great as ever.
Patient Support • February 05, 2025
Addressing the Unmet Needs of the Amyloidosis Community
We spoke with Cristina Quarta, Executive Medical Director, about a group of rare diseases known as amyloidosis, the medical needs within this community and how her work as a cardiologist shapes her approach to research and development (R&D) for rare cardiac conditions.